GlassScriptPhysician profile
Sherif M Ammar
NPI 1497746598
$2,204.83
in general payments reported to CMS, 2019-2025
30 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $206 · 2021: $28.64 · 2022: $249 · 2023: $576 · 2024: $529 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $394.15 | 2019-2022 | |
| Janssen Biotech, INC. | $244.43 | 2019-2025 | Tecvayli, Darzalex, Tremfya |
| Sun Pharmaceutical Industries INC. | $136.17 | 2020-2025 | Ilumya |
| Takeda Pharmaceuticals U.S.A., INC. | $134.76 | 2023-2025 | Alunbrig |
| Astrazeneca Pharmaceuticals LP | $126.24 | 2023-2025 | Enhertu, Imfinzi, Tagrisso |
| Lilly USA, LLC | $107.30 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Blueprint Medicines Corporation | $106.75 | 2023-2024 | Ayvakit |
| Seagen INC. | $99.12 | 2022-2023 | Tukysa |
| Glaxosmithkline, LLC. | $90.54 | 2023-2024 | Ojjaara |
| Amgen INC. | $81.82 | 2019-2024 | Otezla |
| Sobi, INC | $78.24 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $67.61 | 2019 | |
| Beigene USA, INC. | $59.10 | 2024 | Brukinsa |
| Ucb, INC. | $52.20 | 2024-2025 | Bimzelx |
| Adc Therapeutics America, INC. | $48.38 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $43.80 | 2021-2023 | Valchlor |
| E.R. Squibb & Sons, L.L.C. | $39.30 | 2022-2024 | Opdualag |
| Exelixis INC. | $37.12 | 2021-2024 | Cabometyx |
| Daiichi Sankyo INC. | $31.91 | 2022-2023 | Injectafer |
| Smith+Nephew, INC. | $30.41 | 2022-2023 | Grafix Pl |
| Recordati_rare_diseases_inc. | $24.23 | 2024 | Sylvant |
| Biofrontera INC. | $22.13 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Genzyme Corporation | $21.92 | 2023 | |
| Emd Serono, INC. | $20.49 | 2023 | Tepmetko |
| Deciphera Pharmaceuticals INC. | $19.81 | 2024 | Qinlock |
| Puma Biotechnology, INC. | $19.53 | 2024 | |
| Merck Sharp & Dohme LLC | $18.34 | 2022 | |
| Tesaro, INC. | $18.06 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.40 | 2024 | Pyrukynd |
| Dermira, INC. | $14.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Ammar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.